Yes. Dana-Farber Cancer Institute and Array Pharmaceuticals (ARRY) announced an immuno-oncology collaboration with potential applicability in a wide range of cancer indications.
Who are these people, meaning Danna-Faber Cancer institute?
Founded in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been providing cancer patients, including adults and children, with the best treatment available today, while developing tomorrow’s cures through cutting-edge research. The Institute is one of the world’s leading centers of cancer research and treatment. It is ranked in the top 4 of U.S. News and World Report’s Best Hospitals for both adult and pediatric cancer care. As a matter of fact, Dana-Farber is dedicated to a unique, 50/50 balance between cancer research and cancer care. Much of the Institute’s work is translating the results of its discovery into new treatments for patients around the Globe
Yes, the research team at Dana-Farber’s Robert and Renée Belfer Center for Applied Cancer Science decided to work with Array scientists on novel immune-oncology targets with the goal of bringing innovative medicines to the sufferers.
The collaboration is about combining Dana Farber’s oncology expertise with Array’s proficiency in drug discovery. It is about providing a unique opportunity to accelerate drug discovery of effective medicines for patients with unmet medical need.
Kwok-Kin Wong, MD, PhD, scientific co-director of the Belfer Center for Applied Cancer Science and Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School expressed the institute’s enthusiasm about working with Array to develop novel immune-oncology drugs, describing Array’s team as having a strong track record of drug discovery success yielding innovative cancer therapies. Dr. Wong said, “together we have the potential to deliver novel molecules that target unique mechanisms to harness the immune system and result in durable efficacy.”
The Belfer Center for Applied Cancer Science is an industry-inspired cancer research center integrated within the Dana-Farber Cancer Institute dedicated to translating today’s most innovative oncology research into tomorrow’s most promising cancer treatments. The Center is accelerating the development of new cancer immuno-oncology drugs, fighting cancer resistance, pinpointing novel target discovery and blood-based biomarkers.
Prohost never underestimated Array. We always recognized this firm’s scientists’ and science’s capabilities and recognized the fact that its its library of investigational targeted products will be part of the future in the treatment of cancer. This collaboration is great for both Array and the Dana-Farber Institute. It gives Array access to Belfer Center’s portfolio of unlimited technologies and resources, which exist to help academic and industry partners achieve success in developing and bringing to market novel therapeutics for cancer.
We believe that Dana-Farber scientists and Array scientists working together on novel immune-oncology targets will accelerate reaching the goal of bringing innovative medicines to the oncology clinics. The effective combination of immunotherapy drugs with other targeted cancer drugs will be pinpointed and chosen based on scientific data, a capability that will be part of the outcome of this partnership.